Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Kisqali
Kisqali
Novartis drug helps stop breast cancer’s return in large study
Novartis drug helps stop breast cancer’s return in large study
BioPharma Dive
Novartis
Kisqali
clinical trials
breast cancer
Flag link:
ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers
ASCO preview: Merck's Keytruda, Novartis' Kisqali face their moment of truth in early-stage cancers
Fierce Pharma
ASCO 2023
Merck
Keytruda
Novartis
Kisqali
non-small cell lung cancer
early breast cancer
Flag link:
Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
BioSpace
Novartis
clinical trials
Kisqali
breast cancer
Flag link:
Novartis’ Kisqali Hits Mark in Mid-Stage Breast Cancer Trial
Novartis’ Kisqali Hits Mark in Mid-Stage Breast Cancer Trial
BioSpace
Novartis
Kisqali
breast cancer
clinical trials
Flag link:
Novartis presents new Kisqali data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Novartis presents new Kisqali data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Drugs.com
ESMO
Novartis
clinical trials
Kisqali
breast cancer
Flag link:
#ASCO21: Novartis keeps building out survival data for Kisqali, hoping to keep the pressure on Pfizer's Ibrance
#ASCO21: Novartis keeps building out survival data for Kisqali, hoping to keep the pressure on Pfizer's Ibrance
Endpoints
ASCO 2021
Novartis
Kisqali
breast cancer
Flag link:
SABCS: Novartis touts Kisqali's 5-year breast cancer survival, advantage over Pfizer's Ibrance
SABCS: Novartis touts Kisqali's 5-year breast cancer survival, advantage over Pfizer's Ibrance
Fierce Pharma
Novartis
Kisqali
breast cancer
SABCS
Flag link:
Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation
Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation
RAPS.org
breast cancer
FDA
Ibrance
Kisqali
Verzenio
Pfizer
Novartis
Eli Lilly
Flag link:
Novartis' Kisqali sharpens survival edge with second ph3 win
Novartis' Kisqali sharpens survival edge with second ph3 win
Fierce Pharma
Novartis
Kisqali
breast cancer
clinical trials
Flag link:
ASCO: Novartis' Kisqali posts first-in-class survival win in younger women
ASCO: Novartis' Kisqali posts first-in-class survival win in younger women
Fierce Pharma
breast cancer
ASCO 2019
Novartis
clinical trials
Kisqali
Flag link:
NICE spurns Lilly’s breast cancer drug Verzenio in favor of rivals from Pfizer and Novartisspir
NICE spurns Lilly’s breast cancer drug Verzenio in favor of rivals from Pfizer and Novartisspir
Fierce Pharma
Lilly
Verzenio
breast cancer
Pfizer
Ibrance
Novartis
Kisqali
NICE
Flag link:
FDA Approves First Cancer Drug Under New Real Time Review Program
FDA Approves First Cancer Drug Under New Real Time Review Program
CP Wire
FDA
Novartis
Kisqali
breast cancer
Scott Gottlieb
Real Time Oncology Review
Flag link:
FDA Approves First Cancer Drug Under New Real Time Review Program
FDA
Scott Gottlieb
Kisqali
breast cancer
Flag link:
ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?
ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?
Fierce Pharma
Novartis
Kisqali
metastatic breast cancer
ASCO 2018
HR-positive
HER2-negative breast cancer
Flag link:
Cancer Space Update: New Regulatory Status for 3 Major Drugs
Cancer Space Update: New Regulatory Status for 3 Major Drugs
Yahoo/Zacks.com
cancer
Merck
Japan
Keytruda
Seattle Genetics
Adcetris
Novartis
Kisqali
Flag link:
Novartis Gets Second Breakthrough Designation for Kisqali
Novartis Gets Second Breakthrough Designation for Kisqali
Yahoo/Zacks.com
Novartis
Kisqali
breast cancer
Flag link:
In Young Women, Kisqali Slows Metastatic Breast Cancer And Relieves Symptoms
In Young Women, Kisqali Slows Metastatic Breast Cancer And Relieves Symptoms
Forbes
Novartis
Kisqali
metastatic breast cancer
Flag link:
Pfizer's Ibrance, Novartis' Kisqali go to battle in England after discounts twin NICE recommendations
Pfizer's Ibrance, Novartis' Kisqali go to battle in England after discounts twin NICE recommendations
Fierce Pharma
Pfizer
Ibrance
Novartis
Kisqali
England
breast cancer
UK
NICE
Flag link:
Novartis takes fight to Pfizer's Ibrance with new Kisqali data
Novartis takes fight to Pfizer's Ibrance with new Kisqali data
Yahoo/Reuters
Novartis
Pfizer
Ibrance
Kisqali
breast cancer
Flag link:
Latecomer Verzenio stands out from Ibrance, Kisqali in launch's early days: Lilly
Latecomer Verzenio stands out from Ibrance, Kisqali in launch's early days: Lilly
Fierce Pharma
Verzenio
Ibrance
Kisqali
drug launches
breast cancer. Eli Lilly
Pfizer
Novartis
Flag link:
Pages
1
2
next ›
last »